Correlations between Microbiological Outcomes and Clinical Responses in Patients with Severe Pneumonia

Background In treatment of pneumonia, microorganisms sometimes persist, appear or reappear despite good clinical responses. On the other hand, recent increasing antibiotic resistance emphases the goal of rapid eradication of pathogen in severe infection. This study was planned to evaluate the correlations between microbiological outcomes and clinical responses in severe pneumonia. Materials and Methods Data was gathered from 3 clinical trials regarding severe pneumonia. Microbiological outcomes, determined by serial culture of respiratory tract samples,were compared with clinical outcomes. Results In total, 146 bacterial strains from 76 patients were analyzed. While clinical success was generally related to total or partial eradication of isolated organisms, Acinetobacter, Enterobacter, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia were often not eradicated and yet were observed in 56% of cases considered clinically successful at the end of antibiotic treatment. Most of the non-eradicated strains (71%) already had or developed resistance against the antibiotics used for treatment. Ten patients relapsed during the follow-up period; 7 of these relapses were associated with 10 non-eradicated organisms. Conclusions These data raise concern about the pathogenicity of bacteria that persist in the respiratory tract even though good clinical outcomes of pneumonia are achieved, especially when Acinetobacter, Enterobacter, P. aeruginosa, or S. maltophilia were involved. Thus, clinical relapse and development of drug resistance by non-eradicated organisms may be raised.

[1]  R. Wunderink Surrogate markers and microbiologic end points. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  W. Dunne,et al.  Pseudomonas aeruginosa Acquires Biofilm-Like Properties within Airway Epithelial Cells , 2005, Infection and Immunity.

[3]  P Stoodley,et al.  Survival strategies of infectious biofilms. , 2005, Trends in microbiology.

[4]  D. Andersson,et al.  Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. , 2005, The Journal of antimicrobial chemotherapy.

[5]  D. Andersson,et al.  Persistence of antibiotic resistant bacteria. , 2003, Current opinion in microbiology.

[6]  J. Garau Why do we need to eradicate pathogens in respiratory tract infections? , 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[7]  C. Stratton Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance , 2003, Emerging infectious diseases.

[8]  A. Tomasz,et al.  From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae. , 2002, The Journal of antimicrobial chemotherapy.

[9]  F. Baquero,et al.  Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. , 2002, The Journal of antimicrobial chemotherapy.

[10]  A. Prince Biofilms, antimicrobial resistance, and airway infection. , 2002, The New England journal of medicine.

[11]  G. Mccracken,et al.  Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal alpha-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Hugues Berry,et al.  Antibiotic resistance and virulence properties of Pseudomonas aeruginosa strains from mechanically ventilated patients with pneumonia in intensive care units: comparison with imipenem-resistant extra-respiratory tract isolates from uninfected patients. , 2002, Microbes and infection.

[13]  C Peña,et al.  Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. , 2001, JAMA.

[14]  F. Baquero,et al.  Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. , 2001, The Journal of antimicrobial chemotherapy.

[15]  G. Mccracken,et al.  Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  F. Ramisse,et al.  Decreased virulence of a strain of Pseudomonas aeruginosa O12 overexpressing a chromosomal type 1 beta-lactamase could be due to reduced expression of cell-to-cell signaling dependent virulence factors. , 2000, FEMS immunology and medical microbiology.

[17]  B. Levin,et al.  The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.

[18]  D. Greenberg,et al.  Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. , 1998, The Pediatric infectious disease journal.

[19]  Jerome J. Schentag,et al.  Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy , 1998, Antimicrobial Agents and Chemotherapy.

[20]  B. Balkau,et al.  Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. , 1998, JAMA.

[21]  Jerome J. Schentag,et al.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group , 1994, Antimicrobial Agents and Chemotherapy.

[22]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[23]  J. Klein,et al.  Evaluation of New Anti-Infective Drugs for the Treatment of Respiratory Tract Infections , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  D. Gilbert,et al.  General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  F. Pirali,et al.  Reduced virulence in ciprofloxacin-resistant variants of Pseudomonas aeruginosa strains. , 1987, The Journal of antimicrobial chemotherapy.

[26]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[27]  J. Janda,et al.  Phenotypic factors correlated with the absence of virulence among gentamicin-resistant Pseudomonas aeruginosa strains , 1984, Journal of clinical microbiology.